

## Special Issue

# Lynch Syndrome (HNPCC): Symptoms, Causes, and Outlooks

### Message from the Guest Editor

Lynch syndrome (LS) is an autosomal dominant genetic disorder associated with germline mutations in DNA mismatch repair (MMR) genes. Carriers of pathogenic variants in these genes are at increased risk of developing colorectal cancer and/or LS-associated cancer. The loss of the MMR complex determines, at the somatic level (colorectal cancer), a condition defined as microsatellite instability (MSI) or mismatch repair deficiency (dMMR). Unfortunately, not all colorectal cancers with MSI or dMMR have pathogenic germline mutations in the MMR genes. This condition also often occurs in families with a strong predisposition to the development of tumors; therefore, the identification of genetic predisposition as a cause of cancer becomes very important for the preventive management of these families. This Special Issue will highlight all of these aspects of Lynch syndrome in order to advance our knowledge on the best path forward for the management of patients with Lynch syndrome. In this Special Issue, original research articles and reviews are welcome.

### Guest Editor

Dr. Francesca Duraturo

Department of Molecular Medicine and Medical Biotechnology,  
University of Naples Federico II, 80131 Naples, Italy

### Deadline for manuscript submissions

1 March 2026



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/208372](https://mdpi.com/si/208372)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)